On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
The causal association of germline TP53 mutations with development of cancer in individuals with the Li-Fraumeni Syndrome (LFS) cancer predisposition phenotype was initially described in 1990. Since then, technical advances in genetic and genomic sequencing, enhanced understanding of the biology of p53, creation and study of mouse models of p53 deficiency and mutant p53, and extensive annotation of the evolving clinical phenotype has improved our knowledge of this relatively rare syndrome. Several challenges remain to be overcome; these include 1) the molecular landscape of cancers associated with germline TP53 mutations is poorly understood; 2) effective means of tumor prevention and treatment are lacking; and 3) prediction of tumor type or age of onset are difficult. This lecture will examine the progress made to date in understanding the molecular and clinical aspects of the p53-LFS relationship and will explore early clues that will help address the remaining challenges.
